Table 1 Overview of sociodemographic and clinical characteristics by postoperative surgical complications statusa
From: Allostatic load as a predictor of postoperative complications in patients with breast cancer
Patient characteristic | All | Postoperative Surgical Complications | P-Valueb | |
|---|---|---|---|---|
Yes | No | |||
n = (4459) | n = (365) | n = (4094) | ||
Age group, n (%) | 0.103 | |||
≤39 | 313 (7) | 17 (4.7) | 296 (7.2) | |
40–49 | 838 (18.8) | 70 (19.2) | 768 (18.8) | |
50–59 | 1184 (26.6) | 85 (23.3) | 1099 (26.8) | |
60–59 | 1286 (28.8) | 112 (30.7) | 1174 (28.7) | |
70+ | 838 (18.8) | 81 (22.2) | 757 (18.5) | |
Race-ethnicity, n (%) | 0.095 | |||
Hispanic-Black | 3 (0.1) | 0 (0) | 3 (0.1) | |
Non-hispanic-Black | 381 (8.5) | 46 (12.6) | 335 (8.2) | |
Hispanic-White | 23 (0.5) | 1 (0.3) | 22 (0.5) | |
Non-hispanic-White | 3861 (86.6) | 302 (82.7) | 3559 (86.9) | |
Hispanic-other | 27 (0.6) | 3 (0.8) | 24 (0.6) | |
Non-hispanic-other | 164 (3.7) | 13 (3.6) | 151 (3.7) | |
Marital status, n (%) | 0.002 | |||
Single | 639 (14.3) | 63 (17.3) | 576 (14.1) | |
Married/living as married | 2843 (63.8) | 202 (55.3) | 2641 (64.5) | |
Widowed, separated or divorced | 977 (21.9) | 100 (27.4) | 877 (21.4) | |
Health insurance, n (%) | <0.001 | |||
Managed care | 2650 (59.4) | 184 (50.4) | 2466 (60.2) | |
Medicaid | 1365 (30.6) | 130 (35.6) | 1235 (30.2) | |
Medicare | 376 (8.4) | 46 (12.6) | 330 (8.1) | |
Other | 68 (1.5) | 5 (1.4) | 63 (1.5) | |
Smoking history, n (%) | 0.082 | |||
Never | 2787 (62.5) | 211 (57.8) | 2576 (62.9) | |
Current or former | 1672 (37.5) | 154 (42.2) | 1518 (37.1) | |
Alcohol use, n (%) | 0.029 | |||
Never | 2103 (47.2) | 192 (52.6) | 1911 (46.7) | |
Current or former | 2356 (52.8) | 173 (47.4) | 2183 (53.3) | |
Charlson comorbidity indexc, n (%) | <0.001 | |||
0 | 3520 (78.9) | 248 (67.9) | 3272 (79.9) | |
1–3 | 826 (18.5) | 92 (25.2) | 734 (17.9) | |
4+ | 113 (2.5) | 25 (6.8) | 88 (2.1) | |
HER-2+ summary, n (%) | 692 (15.5) | 59 (16.2) | 633 (15.5) | 0.703 |
Progesterone+ summary, n (%) | 3111 (69.8) | 255 (69.9) | 2856 (69.8) | 0.967 |
Estrogen+ summary, n (%) | 3569 (80.0) | 288 (78.9) | 3281 (80.1) | 0.571 |
Molecular subtype, n (%) | 0.796 | |||
Hormone receptor negative/HER 2 positive | 242 (5.4) | 24 (6.6) | 218 (5.3) | |
Hormone receptor positive/HER 2 negative | 2753 (61.7) | 223 (61.1) | 2530 (61.8) | |
Hormone receptor positive/HER2 positive | 818 (18.3) | 66 (18.1) | 752 (18.4) | |
Hormone receptor negative/HER negative | 646 (14.5) | 52 (14.2) | 594 (14.5) | |
Cancer stage, n (%) | 0.206 | |||
1 | 2814 (63.1) | 211 (57.8) | 2603 (63.6) | |
2 | 1369 (30.7) | 121 (33.2) | 1248 (30.5) | |
3 | 276 (6.2) | 33 (9.0) | 243 (5.9) | |
Mastectomy, n (%) | 2124 (47.6) | 187 (51.2) | 1937 (47.3) | 0.151 |
Lumpectomy, n (%) | 2306 (51.7) | 201 (55.1) | 2105 (51.4) | 0.180 |
Sentinel lymph node biopsy only, n (%) | 1444 (32.4) | 94 (25.8) | 1350 (33.0) | 0.005 |
Axillary lymph node biopsy only, n (%) | 237 (5.3) | 20 (5.5) | 217 (5.3) | 0.884 |
Both sentinel and axillary lymph node biopsies, n (%) | 2013 (45.1) | 187 (51.2) | 1826 (44.6) | 0.015 |
Reconstructive surgery | 1156 (25.9) | 78 (21.4) | 1078 (26.3) | 0.038 |
Hormone therapy, n (%) | 3355 (75.2) | 272 (74.5) | 3083 (75.3) | 0.739 |
Radiation therapy, n (%) | 2679 (60.1) | 216 (59.2) | 2463 (60.2) | 0.713 |
Chemotherapy, n (%) | 2112 (47.4) | 184 (50.4) | 1928 (47.1) | 0.224 |
High allostatic load, n (%) | 2202 (49.4) | 213 (58.4) | 1989 (48.6) | <0.001 |
